Skip to main content
. 2016 May 24;7:733. doi: 10.3389/fmicb.2016.00733

Table 2.

Clinical characteristics of the 25 patients sampled in this study.

Patient N° Sex Age Country of birth Background CD4 count (/mm3) Prophylaxis Treatment Outcome at month 3
P1 M 32 Na HIV 48 No Cotrimoxazole Alive
P2 M 50 Haiti HIV 81 No Cotrimoxazole Alive
P3 M 10 Na Systemic lupus erythematosus na na na na
P4 M 47 Metropolitan France HIV 216 No Cotrimoxazole Alive
P5 F 20 Metropolitan France Lymphoma na Pentacarinat Atovaquone Alive
P6 M 65 Vietnam HIV 2 No Pentacarinat Alive
P7 M 45 North Africa Kidney SOT 170 No Cotrimoxazole Alive
P8 M 45 Metropolitan France HIV 2 No Cotrimoxazole Alive
P9 M 42 Metropolitan France Lymphoma na No Cotrimoxazole Alive
P10 M 48 Na HIV na na na na
P11 M 56 Metropolitan France Kidney SOT na No Cotrimoxazole Alive
P12 F 64 Metropolitan France Kidney SOT 59 No Cotrimoxazole Alive
P13 M 33 Metropolitan France HIV 12 No Cotrimoxazole Alive
P14 M 69 Comores Lymphoma 11 No Cotrimoxazole Death
P15 M 66 North Africa HIV 116 No Cotrimoxazole Alive
P16 M 54 Haiti Kidney SOT 268 No Cotrimoxazole na
P17 M 59 Metropolitan France HIV 20 No Cotrimoxazole Alive
P18 M 57 Na Lung cancer na No Cotrimoxazole Alive
P19 M 0.3 Metropolitan France Neonate na na na na
P20 M 50 Metropolitan France HIV 38 No Cotrimoxazole Alive
P21 M 81 Metropolitan France Lymphoma na No Cotrimoxazole Alive
P22 M 56 Metropolitan France Lymphoma 256 No Cotrimoxazole Alive
P23 F 57 Metropolitan France HSCT and Lymphoma 9 Atovacone Cotrimoxazole Death
P24 M 62 Metropolitan France HIV 56 No Cotrimoxazole Alive
P25 M 60 Roumania HIV 10 No Cotrimoxazole Alive

na: not available.